Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides

Virology Journal

Volumn 9, Issue , 2012, Pages

  Fukui, Akimasa ^a   Matsueda, Satoko ^a   Kawano, Kouichiro ^a   Tsuda, Naotake ^a   Komatsu, Nobukazu ^a   Shichijo, Shigeki ^a   Sasada, Tetsuro ^a   Hattori, Satoshi ^b   Ushijima, Kimio ^a   Itoh, Kyogo ^a   Kamura, Toshiharu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

Anti peptide antibody; Human papillomavirus; Prophylactic vaccine; Virus like particles

Indexed keywords

ALUMINUM HYDROXIDE; EPITOPE; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HUMAN PAPILLOMAVIRUS TYPE 16L1 DERIVED PEPTIDE; IMMUNOGLOBULIN G ANTIBODY; PEPTIDE VACCINE; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; UTERINE CERVIX CANCER; VIRUS LIKE AGENT;

ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; FEMALE; HLA-A ANTIGENS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PROTEIN BINDING;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; MUS;

EID: 84866173624     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-199     Document Type: Article

References (14)

1. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. Mũoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, N Engl J Med 2003 348 518 527 10.1056/NEJMoa021641 12571259
2. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E, Lancet Oncol 2005 6 271 278 10.1016/S1470-2045(05)70101-7 15863374
3. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group, Lancet 2004 364 1757 1765 10.1016/S0140-6736(04)17398-4 15541448
4. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. De Carvalho N, Teixeria J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, Sanchez N, Schuind A, Vaccine 2010 28 6247 6255 10.1016/j.vaccine.2010.07.007 20643092
5. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iverson OE, Hernandez-Ailta M, Vaccine 2008 26 6844 6851 10.1016/j.vaccine.2008.09.073 18930097
6. Deletion of a major epitope of human papillomavirus tyle16 virus-like particles. Ryding J, Dahlberg L, Wallen-Ohman M, Dilner J, J Gen Virol 2007 88 792 802 10.1099/vir.0.82449-0 17325351
7. Does T Helper Differentiation Correlate with Resistance or Susceptibility to Infection with L. major? Some Insights From the Murine Model. Tacchini-Cottier F, Weinkopff T, Launois P, Front Immunol 2012 3 32 22566916
8. MHC ligands and peptide motifs: first listing. Rammensee GH, Fried T, Stevanovic S, Immnogenetics 1995 41 178 228 10.1007/BF00172063
9. MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. Guang Lan Z, Khan AM, Srinivasan KN, August JT, Brusic V, Nucleic Acids Res 2005 33 172 179
10. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichijo S, Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K, Yamana H, Clin Cancer Res 2004 10 3 929 937 10.1158/1078-0432.CCR-1117-3 14871969
11. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. Imanishi T, Akazawa T, Kimura A, HLA 1991 Oxford Scientific Publications, Oxford, Tsuji K, Aizawa M, Sasazuki T, 1992 1065 1220
12. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garçon N, J Immunol 2009 183 10 6186 6197 10.4049/jimmunol.0901474 19864596
13. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Komatsu N, Shichijo S, Nakagawa M, Itoh K, Scand J Clin Lab Invest 2004 64 535 546 10.1080/00365510410007008 15370458
14. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, Itoh K, J Immunol 2000 164 5 2565 2574 10679095